Edap Tms (NASDAQ: EDAP) and Derma Sciences (NASDAQ:DSCI) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.
Earnings and Valuation
This table compares Edap Tms and Derma Sciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Edap Tms||$39.28 million||1.99||$4.25 million||($0.08)||-33.75|
This is a breakdown of current ratings and recommmendations for Edap Tms and Derma Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Edap Tms currently has a consensus target price of $6.50, indicating a potential upside of 140.74%. Given Edap Tms’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Edap Tms is more favorable than Derma Sciences.
This table compares Edap Tms and Derma Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
10.3% of Edap Tms shares are held by institutional investors. Comparatively, 58.9% of Derma Sciences shares are held by institutional investors. 9.9% of Derma Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Edap Tms beats Derma Sciences on 8 of the 11 factors compared between the two stocks.
About Edap Tms
EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.
About Derma Sciences
Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.